NUCLEAR MEDICINE

Therapy in Thyroid Cancer

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Therapy in Thyroid Cancer

Substance class Drug Available data Retinoids Retinoic acid Phase-I/II-studies and numerous observation studies Retinoid-X-receptor-ligand Bexarotene (300 mg) Phase-I/II-study (8 patients) Agonists of the “peroxisome-proliferator activated receptor gamma” (PPAR-g) Rosiglitazone Phase-I/II-study (10…

read more

Iodide Symporter in Thyroid Carcinoma

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Iodide Symporter in Thyroid Carcinoma

Fig. 1 Sodium iodide symporter Several anions are transported by NIS, namely, I, SeCN, SCN, ClO3, and NO3 (in descending order of affinity). NIS also transports technetium pertechnetate and rhenium perrhenate….

read more

Remnant Ablation: A Critical Review

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Remnant Ablation: A Critical Review

First author, year Country Patients enrolled (n) TNM Pathology (P/F) Type of surgery Dose (mCi) Follow-up time (mo) Definition of successful ablation Method of preparation Bal, 1996 India 149 TxNxMo…

read more

Considerations for Timely Development of Therapeutic Radiopharmaceuticals

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Considerations for Timely Development of Therapeutic Radiopharmaceuticals

© Springer-Verlag Berlin Heidelberg  2012Richard P. Baum (ed.)Therapeutic Nuclear MedicineMedical Radiology10.1007/174_2012_698 Pharma Considerations for Timely Development of Therapeutic Radiopharmaceuticals Adrian D. Nunn1   (1) Bracco Research USA Ltd, ⌦, 305 College Road East, Princeton, NJ 08540,…

read more
Get Clinical Tree app for offline access